Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID
Statera Biopharma (Nasdaq: STAB) announced the enrollment of the first patient in a clinical study for STAT-205, an immune-modulating treatment aimed at mitigating COVID-19 progression. The randomized, placebo-controlled trial will assess the pharmacokinetics, biomarkers, and safety of STAT-205. The study targets 24 patients with mild symptoms and high disease progression risk. Preliminary results are expected in 2022. This development emphasizes Statera's commitment to innovative therapies that address COVID-19 and enhance immune response.
- Enrollment of the first patient in the clinical trial for STAT-205.
- Focus on developing a cost-effective therapeutic option for COVID-19.
- Preliminary results anticipated in 2022, potentially impacting the pandemic landscape.
- None.
Initial Study to Evaluate Pharmacokinetics, Biomarkers and Safety of STAT-205
Targeting Preliminary Data 2022
FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today the enrollment and randomization of the first patient, with several more in screening for an initial study to evaluate STAT-205 as a potential treatment to mitigate SARS-CoV-2 progression, the virus that causes COVID-19. STAT-205 is an immune-modulator designed to decrease elevated inflammatory responses associated with cytokine production and modulate the Th1/Th2 helper cells to control immune dysfunction.
“We look forward to working with the researchers to explore the potential of STAT-205 as an oral cost-effective therapeutic option for patients with COVID-19,” stated Michael K. Handley, President and Chief Executive Officer, Statera Biopharma. “We expect preliminary trial results to be reported in 2022.”
“Now that vaccines are widely available, developing safe and effective treatments for people who contract COVID-19 is our next challenge. Statera Biopharma is one of the first companies to modulate the immune system function to decrease elevated inflammatory responses associated with SARS-CoV-2 viral infections,” said George P. Azar Jr., MD, FCCP, Board Certified Pulmonologist of the Clinical Research Center of Florida. “This approach has the potential improve outcomes for countless patients and impact the landscape of the pandemic with a cost-effective therapeutic treatment for COVID-19. I am excited that our site has randomized the first patient in the clinical trial of STAT-205.”
The randomized, single-blind, placebo-controlled study will enroll 24 patients that are age 18 years or older who test positive for acute SARS-CoV-2 and show symptoms of mild infection that are at high risk for disease progression. The study is designed to assess the pharmacokinetics (PK), early predictive biomarkers, and safety of STAT-205.
In preclinical in vitro studies, STAT-205 demonstrated the potential to inhibit the replication of coronaviruses in human lung cells.
About Statera Biopharma
Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis. To learn more about Statera Biopharma, please visit www.staterabiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical fact contained in this press release, including statements regarding the Company's expected clinical development timeline for the Company's product candidates, future financial position, business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals, the impact of any laws or regulations applicable to the company, and plans and objectives of management for future operations, are forward-looking statements. The words "anticipate," "believe," "continue," "should," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements on the current expectations about future events held by management. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond the Company's control. The company's actual future results may differ materially from those discussed here for various reasons. The Company discusses many of these risks under the heading "Risk Factors" in the proxy statement/prospectus filed with the SEC on June 10, 2021, as updated by the company's other filings with the SEC. Factors that may cause such differences include, but are not limited to, the outcome of any legal proceedings that have been or may be instituted against the company related to the merger between Cleveland BioLabs and Cytocom; unexpected costs, charges or expenses resulting from the merger; the Company's need for additional financing to meet the Company's business objectives; the Company's history of operating losses; the Company's ability to successfully develop, obtain regulatory approval for, and commercialize the Company's products in a timely manner; the Company's plans to research, develop and commercialize the Company's product candidates; the Company's ability to attract collaborators with development, regulatory and commercialization expertise; the Company's plans and expectations with respect to future clinical trials and commercial scale-up activities; the Company's reliance on third-party manufacturers of the Company's product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to serve those markets; the rate and degree of market acceptance of the Company's product candidates; regulatory requirements and developments in the United States, the European Union and foreign countries; the performance of the Company's third-party suppliers and manufacturers; the success of competing therapies that are or may become available; the Company's ability to attract and retain key scientific or management personnel; the Company's historical reliance on government funding for a significant portion of the Company's operating costs and expenses; government contracting processes and requirements; the exercise of significant influence over the Company's company by the Company's largest individual stockholder; the impact of the novel coronavirus ("COVID-19") pandemic on the Company's business, operations and clinical development; the geopolitical relationship between the United States and the Russian Federation as well as general business, legal, financial and other conditions within the Russian Federation; the Company's ability to obtain and maintain intellectual property protection for the Company's product candidates; the Company's potential vulnerability to cybersecurity breaches; and other factors discussed in the Company's SEC filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and the risk factors discussed under the heading "Risk Factors" in the proxy statement/prospectus the company filed in connection with the merger on June 10, 2021. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.
Contacts:
Statera Biopharma
Nichol Ochsner
Executive V.P. Investor Relations and Corporate Communications
+1.732.754.2545
nichol.ochsner@staterabiopharma.com
FINN Partners
Glenn Silver
glenn.silver@finnpartners.com
+1.973.818.8198
FAQ
What is the purpose of the STAT-205 study?
How many patients will be enrolled in the STAT-205 study?
When are preliminary results for the STAT-205 study expected?
What type of clinical study is being conducted for STAT-205?
What is the stock symbol for Statera Biopharma?
